Heron Therapeutics Inc(HRTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.19 | Insider Own | 1% | Shs Outstand | 189.5M | Perf Week | -16.68% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 15.38% | Insider Trans | - | Shs Float | 187.9M | Perf Month | 2.21% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | -0.03 | Inst Own | 69.62% | Short Float | 24.49% | Perf Quarter | -38.11% |
| Income | -0.03B | P/S | 0.38 | EPS this Y | -8.33% | Inst Trans | -10.68% | Short Ratio | 18.43 | Perf Half Y | -74.73% |
| Sales | 0.15B | P/B | 9.73 | EPS next 5Y | 22.9% | ROA | -14.06% | Short Interest | 46.02M | Perf YTD | -76.87% |
| Book/sh | 0.03 | P/C | 1.34 | EPS past 3/5Y | 58.31% 45.44% | ROE | - | 52W High | -80.91% ($1.58) | Perf Year | -74.94% |
| Cash/sh | 0.22 | P/FCF | - | Sales past 3/5Y | 12.89% 11.81% | ROIC | -21.96% | 52W Low | 15.21% ($0.26) | Perf 3Y | -50.03% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -3014.75% | Gross Margin | 70.07% | Volatility(W/M) | 11.52% 12.28% | Perf 5Y | -97.07% |
| Dividend TTM | - | EV/Sales | 1.08 | Sales Y/Y TTM | 0.99% | Oper. Margin | -6.99% | ATR (14) | 0.04 | Perf 10Y | -98.09% |
| Dividend Ex-Date | - | Quick Ratio | 1.51 | EPS Q/Q | -85.81% | Profit Margin | -22.52% | RSI (14) | 40.88 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.49 | Sales Q/Q | 1.25% | SMA20 | -14.49% ($0.35) | Beta | 1.65 | Target Price | $0.34 |
| Payout | - | Debt/Eq | 21.47 | Earnings | 2026/8/10 | SMA50 | -8.67% ($0.33) | Rel Volume | 0.42 | Prev Close | $0.3 |
| Employees | 128 | LT Debt/Eq | 21.44 | EPS/Sales Surpr. | -500% -10.72% | SMA200 | -58.47% ($0.72) | Avg Volume(3M) | 2.50M | Price | $0.3 |
| IPO | 1987/8/26 | Option/Short | Yes/Yes | Trades | 2102 | Volume | 1,056,084 | Change | -0.69% |
A U.S. biotech company that develops and commercializes pharmaceutical products focused on acute pain management and supportive cancer care. Leveraging its proprietary drug delivery technology, the company markets a post-surgical pain management agent and an antiemetic for controlling nausea and vomiting associated with chemotherapy, distributing its products primarily through hospitals and surgical centers.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 42% of its average volume.
HRTX has a sound balance sheet but weak earning power
Of every $100 in sales, $6.99 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -8.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $38. Peers typically go for $951.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.1%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
24.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #400 of 594 in the industry
Based on market cap of $57M.
PTHS#398 Pelthos Therapeutics Inc $58M PER - 
APLM#399 Apollomics Inc $58M PER - HRTX#400 Heron Therapeutics Inc $57M PER - 
OSTX#401 OS Therapies Inc $57M PER - 
XBIT#402 XBiotech Inc $56M PER - 
FAQ
What kind of company is HRTX?
HRTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HRTX?
The market cap of HRTX is approximately $57M, ranking 4,768 within its sector.
What is the 52-week high and low for HRTX?
HRTX has recorded a 52-week high of $1.58 and a low of $0.26.
